Philip Morris considers selling stake in pharmaceuticals unit to boost healthcare division

Philip Morris considers selling stake in pharmaceuticals unit to boost healthcare division


In this photo illustration a Vectura Group plc logo is seen on a smartphone and a pc screen.

Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images

Philip Morris International is considering selling off a stake in its largest pharmaceuticals unit.

The tobacco company, which makes Marlboro cigarettes, made inroads into the healthcare and wellness space in 2021 with the acquisition of Vectura, a UK-based pharmaceutical company that makes inhaled medicines and inhaler devices.

But more recently the division has struggled, and Philip Morris has had talks with Deutsche Bank on a range of options to try to grow its wellness and healthcare division, the WSJ first reported.

The company has been looking for a new partner to help boost Vectura, and it’s contemplating different options including a licensing or royalties deal, a commercial partnership, or a sale of a majority or minority stake in the business.

In recent years, Philip Morris has also acquired Fertin Pharma, a nicotine gum maker, and OtiTopic, a respiratory drug maker.

The three deals, which together totaled more than $2 billion, were a part of the company’s broader, long-term pivot toward developing smoke-free products and medicines aimed at treating respiratory diseases commonly associated with cigarette smoking.

The acquisitions, however, triggered backlash from the public health sector. And, in the second quarter of this year, the company took a $680 million impairment charge related to its wellness and healthcare division.

At the time of the Vectura deal, PMI said the acquisition would grow its “Beyond Nicotine” business and help the division achieve its goal of generating at least $1 billion in net revenues from these products by 2025. Following the setbacks, PMI walked back that goal and said it would begin reducing its investments in the division.

The company, in its Q2 earnings call, said it nevertheless will “remain committed to developing” its wellness and healthcare business and that it plans to “accelerate Vectura’s growth and will be exploring potential partnerships.”

The news comes as the tobacco company continues to face resistance from public health groups. This week, PMI had its CEO removed from the line-up at the Concordia Annual Summit, a side event to the UN General Assembly meeting held in New York every September, after health experts refused to speak at the conference in protest against his appearance.

Concordia also rescinded Philip Morris’s membership in the conference effective immediately.



Source

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Health

Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs. […]

Read More
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Health

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

U.S. President Donald Trump, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, David Sacks, AI & Crypto Czar and Amy Gleason, Acting Administrator, Department of Government Efficiency (DOGE) attend the “Making Health Technology Great Again” event in the East Room […]

Read More
Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Health

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. Nurphoto | Nurphoto | Getty Images Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s […]

Read More